VBI Vaccines Analyst Ratings
VBI Vaccines Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/11/2022 | 236.7% | Raymond James | $5 → $2 | Downgrades | Strong Buy → Outperform |
| 08/09/2022 | 741.75% | Raymond James | $6 → $5 | Maintains | Strong Buy |
| 03/08/2022 | 910.1% | Raymond James | $9 → $6 | Maintains | Strong Buy |
| 08/27/2020 | 1415.15% | Raymond James | $8 → $9 | Upgrades | Outperform → Strong Buy |
| 07/22/2020 | 1246.8% | Raymond James | $3 → $8 | Maintains | Outperform |
| 11/14/2019 | 405.05% | Raymond James | → $3 | Initiates Coverage On | → Outperform |
| 01/16/2019 | 1415.15% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 07/27/2018 | 1920.2% | BMO Capital | $13 → $12 | Maintains | Outperform |
| 11/15/2017 | 1751.85% | BMO Capital | → $11 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/11/2022 | 236.7% | 雷蒙德·詹姆 | 5 美元 → 2 美元 | 降级 | 强势买入 → 跑赢大盘 |
| 08/09/2022 | 741.75% | 雷蒙德·詹姆 | 6 美元 → 5 美元 | 维护 | 强势买入 |
| 03/08/2022 | 910.1% | 雷蒙德·詹姆 | 9 美元 → 6 美元 | 维护 | 强势买入 |
| 08/27/2020 | 1415.15% | 雷蒙德·詹姆 | 8 美元 → 9 美元 | 升级 | 跑赢大盘 → 强势买入 |
| 2020 年 7 月 22 日 | 1246.8% | 雷蒙德·詹姆 | 3 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 11/14/2019 | 405.05% | 雷蒙德·詹姆 | → 3 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 01/16/2019 | 1415.15% | 奥本海默 | → 9 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 07/27/2018 | 1920.2% | BMO Capital | 13 美元 → 12 美元 | 维护 | 跑赢大盘 |
| 11/15/2017 | 1751.85% | BMO Capital | → 11 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
VBI Vaccines Questions & Answers
VBI 疫苗问题与解答
The latest price target for VBI Vaccines (NASDAQ: VBIV) was reported by Raymond James on November 11, 2022. The analyst firm set a price target for $2.00 expecting VBIV to rise to within 12 months (a possible 236.70% upside). 3 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯于2022年11月11日公布了VBI疫苗（纳斯达克股票代码：VBIV）的最新目标价格。该分析公司将目标股价定为2.00美元，预计VBIV将在12个月内升至12个月内（可能上涨236.70％）。去年有3家分析公司公布了评级。
The latest analyst rating for VBI Vaccines (NASDAQ: VBIV) was provided by Raymond James, and VBI Vaccines downgraded their outperform rating.
VBI Vaccines（纳斯达克股票代码：VBIV）的最新分析师评级由雷蒙德·詹姆斯提供，VBI Vaccines下调了跑赢大盘的评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VBI Vaccines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VBI Vaccines was filed on November 11, 2022 so you should expect the next rating to be made available sometime around November 11, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与VBI Vaccines的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。VBI Vaccines的最新评级是在2022年11月11日提交的，因此您应该预计下一个评级将在2023年11月11日左右公布。
While ratings are subjective and will change, the latest VBI Vaccines (VBIV) rating was a downgraded with a price target of $5.00 to $2.00. The current price VBI Vaccines (VBIV) is trading at is $0.59, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的VBI疫苗（VBIV）评级已下调，目标股价为5.00美元至2.00美元。VBI Vaccines（VBIV）的当前交易价格为0.59美元，超出了分析师的预期区间。